A number of key stocks could see notable price action today as major corporate developments unfold. From expansion deals and contract wins to regulatory updates and investment moves, here’s what’s driving these companies.

Infosys Expands U.S. Partnership with Citizens Bank

Infosys has strengthened its relationship with Citizens, one of the oldest and largest financial institutions in the United States. This expansion signals deeper collaboration in digital transformation initiatives, potentially boosting Infosys’ revenue from the financial services sector. Investors will be closely watching how this partnership translates into financial performance.

BEL Secures ₹2,463 Crore Defence Contract

Bharat Electronics Ltd. (BEL) has signed a significant contract with the Ministry of Defence to supply and maintain Ashwini radars for the Indian Air Force. This deal, valued at ₹2,463 crore, underscores BEL’s growing role in India’s defense modernization efforts.

The Ashwini radar is an indigenous 4D Active Electronically Scanned Array (AESA) radar.
It enhances surveillance and tracking capabilities for the Air Force.
The deal is expected to boost BEL’s order book and revenue outlook for the coming quarters.

NHPC Board to Discuss Borrowing Plans

NHPC’s Board of Directors is set to meet on March 19 to discuss its borrowing strategy for the 2025-26 financial year. Given the company’s focus on expanding its hydroelectric projects, investors will keep an eye on any major funding decisions that could impact future growth and capital expenditure plans.

NTPC Green Commissions Final Phase of Solar Project

NTPC Renewable Energy, a subsidiary of NTPC Green, has successfully completed the final 50 MW phase of its 105 MW Shajapur solar project (Unit-1). The milestone reflects NTPC’s continued expansion in renewable energy, aligning with India’s broader push for clean energy.

One-liner insight: With solar capacity additions picking up pace, NTPC Green remains a stock to watch in the renewable energy segment.

Zydus Lifesciences Ventures into Sickle Cell Disease Treatment

Zydus Lifesciences, through its venture capital arm Zynext Ventures USA LLC, has invested in Illexcor Therapeutics. The biopharmaceutical firm is focused on next-generation oral therapies for sickle cell disease (SCD), marking a strategic move by Zydus into niche healthcare solutions. This investment could open new revenue streams in the high-demand rare disease market.

Jubilant Pharma’s USFDA Update

Jubilant Cadista Pharmaceuticals Inc., the U.S.-based unit of Jubilant Pharma, has received the Establishment Inspection Report (EIR) from the USFDA for its Salisbury facility. The “Voluntary Action Indicated” (VAI) status suggests that while some corrective actions were needed, no further regulatory action is anticipated. This could bring a sigh of relief for investors, as compliance with U.S. regulations remains a critical factor for Indian pharma exports.

Vedanta’s Promoters Retain Majority Stake in Demerged Entities

Vedanta has confirmed that its promoters will maintain over 50% stake in each of its demerged companies. This restructuring move aims to create specialized entities that can better tap into emerging opportunities in their respective sectors. Investors will be keen to understand how this restructuring impacts overall valuation and strategic focus.